Although studies have only been performed in cell culture, we highlight three OGT inhibitors: (i) ST045849 (1; Scheme 1 in Supplementary Material) that has been used successfully in the inhibition of prostate cancer cell lines (16); (ii) ST060266 or BZX (2; Scheme 1), an irreversible inhibitor of OGT used in different cell types (49); and (iii) 4Ac-5S-GlcNAc, a cell-permeable compound that enters the HBP to be synthesized into UDP-5S-GlcNAc (3; Scheme 1), a potent OGT inhibitor (52). Here, OGT is linked to prostate cancer.